148 related articles for article (PubMed ID: 37818869)
41. Application of immunohistochemistry to the diagnosis of salivary gland tumors.
de Araújo VC; de Sousa SO; Carvalho YR; de Araújo NS
Appl Immunohistochem Mol Morphol; 2000 Sep; 8(3):195-202. PubMed ID: 10981871
[TBL] [Abstract][Full Text] [Related]
42. Frankly Invasive Carcinoma Ex-intraductal Carcinoma: Expanding on an Emerging and Perplexing Concept in Salivary Gland Tumor Pathology.
McLean-Holden AC; Rooper LM; Lubin DJ; Magliocca KR; Manucha V; Sadow PM; Tobias J; Vargo RJ; Thompson LDR; Heidarian A; Weinreb I; Wenig B; Gagan J; Hernandez-Prera JC; Bishop JA
Head Neck Pathol; 2022 Sep; 16(3):657-669. PubMed ID: 34985683
[TBL] [Abstract][Full Text] [Related]
43. Salivary gland-type tumors of the breast: a spectrum of benign and malignant tumors including "triple negative carcinomas" of low malignant potential.
Foschini MP; Krausz T
Semin Diagn Pathol; 2010 Feb; 27(1):77-90. PubMed ID: 20306833
[TBL] [Abstract][Full Text] [Related]
44. Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma.
Bishop JA; Yonescu R; Batista D; Begum S; Eisele DW; Westra WH
Hum Pathol; 2013 Oct; 44(10):1982-8. PubMed ID: 23773480
[TBL] [Abstract][Full Text] [Related]
45. Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies.
Rodriguez CP; Martins RG; Baik C; Chow LQ; Santana-Davila R; Goulart BH; Lee S; Eaton KD
Head Neck; 2018 Mar; 40(3):584-589. PubMed ID: 29283469
[TBL] [Abstract][Full Text] [Related]
46. A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer.
Shafique M; Ismail-Khan R; Extermann M; Sullivan D; Goodridge D; Boulware D; Hogue D; Soliman H; Khong H; Han HS
Oncologist; 2019 Jul; 24(7):887-e416. PubMed ID: 30996012
[TBL] [Abstract][Full Text] [Related]
47. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Vogl DT; Dingli D; Cornell RF; Huff CA; Jagannath S; Bhutani D; Zonder J; Baz R; Nooka A; Richter J; Cole C; Vij R; Jakubowiak A; Abonour R; Schiller G; Parker TL; Costa LJ; Kaminetzky D; Hoffman JE; Yee AJ; Chari A; Siegel D; Fonseca R; Van Wier S; Ahmann G; Lopez I; Kauffman M; Shacham S; Saint-Martin JR; Picklesimer CD; Choe-Juliak C; Stewart AK
J Clin Oncol; 2018 Mar; 36(9):859-866. PubMed ID: 29381435
[TBL] [Abstract][Full Text] [Related]
48. Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancer.
van Boxtel W; Uijen MJM; Krens SD; Dijkema T; Willems SM; Jonker MA; Pegge SAH; van Engen-van Grunsven ACH; van Herpen CML
Eur J Cancer; 2022 Jan; 161():128-137. PubMed ID: 34920917
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck.
Hong MH; Kim CG; Koh YW; Choi EC; Kim J; Yoon SO; Kim HR; Cho BC
Head Neck; 2018 Jan; 40(1):55-62. PubMed ID: 29044862
[TBL] [Abstract][Full Text] [Related]
50. CK7+/CK20- immunoexpression profile is typical of salivary gland neoplasia.
Meer S; Altini M
Histopathology; 2007 Jul; 51(1):26-32. PubMed ID: 17593078
[TBL] [Abstract][Full Text] [Related]
51. NR4A3 Immunohistochemistry Reliably Discriminates Acinic Cell Carcinoma from Mimics.
Wong KS; Mariño-Enriquez A; Hornick JL; Jo VY
Head Neck Pathol; 2021 Jun; 15(2):425-432. PubMed ID: 32910350
[TBL] [Abstract][Full Text] [Related]
52. Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.
Thorpe LM; Schrock AB; Erlich RL; Miller VA; Knost J; Le-Lindqwister N; Jujjavarapu S; Ali SM; Liu JJ
Head Neck; 2017 Mar; 39(3):E40-E44. PubMed ID: 28006087
[TBL] [Abstract][Full Text] [Related]
53. Comparison of gene fusion detection methods in salivary gland tumors.
Sun L; Petrone JS; McNulty SN; Evenson MJ; Zhu X; Robinson JA; Chernock RD; Duncavage EJ; Pfeifer JD
Hum Pathol; 2022 May; 123():1-10. PubMed ID: 35183572
[TBL] [Abstract][Full Text] [Related]
54. Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia.
Sweet K; Komrokji R; Padron E; Cubitt CL; Turner JG; Zhou J; List AF; Sallman DA; Dawson JL; Sullivan DM; Chavez J; Shah BD; Lancet JE
Clin Cancer Res; 2020 Jan; 26(1):54-60. PubMed ID: 31636097
[TBL] [Abstract][Full Text] [Related]
55. [Expression of NR4A3/NOR-1 in acinic cell carcinoma of the salivary gland].
Cheng K; Wang X; Wei X; Ma J; Xia QY; Shi QL; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1142-1146. PubMed ID: 33152819
[No Abstract] [Full Text] [Related]
56. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.
Keam B; Kim SB; Shin SH; Cho BC; Lee KW; Kim MK; Yun HJ; Lee SH; Yoon DH; Bang YJ
Cancer; 2015 Aug; 121(15):2612-7. PubMed ID: 25903089
[TBL] [Abstract][Full Text] [Related]
57. Utility of neck dissection for management of carcinoma of the parotid gland.
Kaura A; Kennedy RA; Ali S; Odell E; Simo R; Jeannon JP; Oakley R
Br J Oral Maxillofac Surg; 2019 Dec; 57(10):1039-1043. PubMed ID: 31564483
[TBL] [Abstract][Full Text] [Related]
58. GATA3 immunohistochemical expression in salivary gland neoplasms.
Schwartz LE; Begum S; Westra WH; Bishop JA
Head Neck Pathol; 2013 Dec; 7(4):311-5. PubMed ID: 23604756
[TBL] [Abstract][Full Text] [Related]
59. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
Bahlis NJ; Sutherland H; White D; Sebag M; Lentzsch S; Kotb R; Venner CP; Gasparetto C; Del Col A; Neri P; Reece D; Kauffman M; Shacham S; Unger TJ; Jeha J; Saint-Martin JR; Shah J; Chen C
Blood; 2018 Dec; 132(24):2546-2554. PubMed ID: 30352784
[TBL] [Abstract][Full Text] [Related]
60. Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid Cystic Carcinoma-Specific Prognostic Relevance.
Siqueira JM; Mitani Y; Hoff CO; Bonini F; Guimaraes de Sousa L; Marques-Piubelli ML; Purushothaman A; Mitani M; Dai H; Lin SY; Spiotto MT; Hanna EY; McGrail DJ; El-Naggar AK; Ferrarotto R
Mod Pathol; 2024 Jan; 37(1):100371. PubMed ID: 38015043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
